PDS Biotechnology Corp PDSB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
-
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
-
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
-
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
-
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
-
PDS Biotech Reports Second Quarter 2026 Financial Results
-
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Trading Information
- Previous Close Price
- $1.16
- Day Range
- $1.06–1.13
- 52-Week Range
- $0.20–1.79
- Bid/Ask
- $1.08 / $1.09
- Shares Outstanding
- 72.47M
- Market Cap
- $78.28M
- Volume/Avg
- 1M / 24M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.pdsbiotech.com
Valuation
|
Metric
|
PDSB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PDSB
Financial Strength
|
Metric
|
PDSB
|
|---|---|
Quick Ratio | 0.45 |
Current Ratio | 0.57 |
Interest Coverage | −4.18 |
Quick Ratio
PDSB
Profitability
|
Metric
|
PDSB
|
|---|---|
Return on Assets (Normalized) | −90.61% |
Return on Equity (Normalized) | −360.47% |
Return on Invested Capital (Normalized) | −89.19% |
Return on Assets
PDSB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|lv>!Yg | LOCK|?z?> | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|DX@gw!N | LOCK|^ByV | $84B | |||
| Moderna Inc
MRNA
| LOCK|&DkS%?> | LOCK|hq | $81B | |||
| argenx SE ADR
ARGX
| LOCK|&$$xy@ | LOCK|S% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FvHY>n> | LOCK|L%$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@@&&x? | LOCK|Y&<Fz | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#yp#VQ!l | LOCK|&$Jt | $28B | |||
| Incyte Corp
INCY
| LOCK|Pdf#>Fg | LOCK|tqM | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Ch<K## | LOCK|%% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|P>$??X | LOCK|M? | $14B |
United States